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Abstract
A 27-year-old woman of Moldavian origin presented at the age of 15 with progressive proximal limb
weakness and painful cramps in her calf muscles. Clinical examination revealed prominent muscle
weakness in proximal muscles of the lower extremities and distal anterior compartment of legs, and
mild weakness in shoulder girdle muscles. In addition, she had marked calf hypertrophy, muscle
atrophy involving the anterior and posterior compartments of the thighs, and the distal anterior
compartment of legs, as well as mild scapular winging and hyperlordosis. A muscle biopsy taken
from the biceps brachii showed mild dystrophic changes, absent vacuoles, and abundant lobulated
fibers. Immunofluorescence and Western blot assays demonstrated complete telethonin deficiency.
Molecular analysis revealed a homozygous Trp25X mutation in the telethonin (TCAP) gene resulting
in termination of transcription at an early point. Four families from Brazil with telethonin deficiency
have previously been reported and classified as LGMD2G, but the actual frequency of this disease
is unknown. With this current identification of a case outside the Brazilian population, telethonin
mutation-associated LGMD should be considered worldwide.
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1. Introduction
Moreira et al. [1,2] reported a relatively mild form of autosomal recessive limb-girdle muscular
dystrophy (LGMD) in three interrelated Brazilian families and mapped this syndrome to
chromosome 17q11-12. They subsequently discovered a causative mutation in the sarcomeric
protein telethonin [2], and demonstrated telethonin deficiency in the muscles of the affected
patients [3]. Telethonin is a 19-kDa protein exclusively expressed in adult skeletal and cardiac
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muscle [4,5]. Located at the Z-disc, telethonin provides binding sites to link titin and other Z-
disc-associated proteins during sarcomere assembly. Recent protein interaction studies have
shown that the N-terminal region of titin interacts with the N-terminal region of telethonin
(residues 1–53), making this part of telethonin critically important for proper formation in the
Z-disk structures [6,7]. Telethonin is encoded by the TCAP gene which encompasses two exons
and codes for 167 amino acids. Mutations in the telethonin gene are responsible for LGMD
type 2G [1–3] and a small subset of hypertrophic and dilated cardiomyopathies [8–10].
Furthermore, a TCAP mutation has recently been reported in a patient suffering from intestinal
pseudo-obstruction [11].
2. Materials and methods
2.1. Muscle CT scan
Muscle imaging study was performed using a helical CT scanner (HiSpeed NX/iPRO, GE
Medical Systems Milwaukee, WI). Axial images were obtained at the pelvis, mid-thigh and
mid-calf levels.
2.2. Muscle biopsy
A muscle biopsy taken from left biceps brachii was immediately frozen in liquid nitrogen
chilled isopentane and processed by routine histological and histochemical techniques and for
ultrastructural examination using standard methods.
2.3. Immunofluorescence and immunohistochemistry
Unfixed cryostat sections 6-μm-thick were processed for immunohistochemical analysis by
using the streptavidin–biotin Super Sensitive™ IHC detection system (BioGenex, San Ramon,
CA, USA). Antibodies against dystrophin (dys 1, dys 2 and dys 3), spectrin, utrophin, α-
sarcoglycan, β-sarcoglycan, γ-sarcoglycan, δ-sarcoglycan and dysferlin (all from Novocastra,
Newcastle Upon Tyne, UK) were used at a dilution of 1:10, 1:20, 1:10, 1:100, 1:10, 1:200,
1:100, 1:100, 1:10, and 1:10, respectively. For telethonin immunofluorescence, a mouse
monoclonal antitelethonin antibody (G-11, Santa Cruz, Quimigen, Madrid, Spain) was used
at a dilution of 1:500. The secondary antibody Alexa 488 anti-goat (Molecular Probes, Leyden,
Netherlands) was used at a dilution of 1:400. Sections were mounted with Fluorescent
Mounting Medium (DakoCytomation), sealed and dried overnight at 4°C.
2.4. Western blotting
Western blot analysis was performed using 10% (for telethonin, α-sarcoglycan, γ-sarcoglycan),
9% (for calpain) or 6% (for dystrophin and dysferlin) SDS–PAGE electrophoresis. Briefly,
extracted muscle proteins were transferred to nitrocellulose membrane in a Semi-Dry Transfer
System (Bio-Rad, Madrid, Spain). The corresponding membranes were blocked and incubated
with the mouse anti-telethonin antibody at a dilution of 1:1000, or with antibodies against
dystrophin (dys 1 and dys 2), α-sarcoglycan, and calpain (calp 12a2, and calp 2c4, both from
Novocastra, Newcastle Upon Tyne, UK) at a dilution of 1:250, 1:25, 1:50, 1:100, 1:100 and
1:30, respectively. Subsequently, the membranes were washed and then incubated with the
corresponding secondary antibody labeled with horseradish peroxidase (Dako, Barcelona,
Spain). The protein bands were detected by chemiluminescence ECL method (Amersham
Biosciences, Little Chalfont, UK). The myosin band of 205-kDa stained with Coomassie
Brilliant Blue R (Sigma) in the post-transfer gel was used as control of protein loading. For
comparative purposes samples from eight patients suffering from a variety of muscle disorders
(LGMD 2I, n = 1, LGMD 2B, n = 1, BMD, N = 2, myotilinopathy, n = 1, LGMD 2A, n = 2),
and a healthy control were processed in parallel.
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2.5. Telethonin (TCAP) gene analysis
The patient, her parents and her sibling were screened for the presence of mutations in the
telethonin (TCAP) gene. Genomic DNA was extracted from peripheral lymphocytes and used
as a template for polymerase chain reaction (PCR) amplification of each theletonin exon with
intronic primers. Amplified fragments were purified using QIAquick PCR purification Kit
(Qiagen) and directly sequenced using DyeTerminator™ Sequencing Protocol (Applied
Biosystems). To determine whether the identified TCAP mutation is a common DNA variation,
we screened by sequencing 154 individuals, 96 from Poland and the rest from the UK.
3. Results
3.1. Clinical manifestations
The patient presented at the age of 15 years with bilateral proximal weakness in the lower
extremities expressed by progressive difficulty in running, climbing stairs and standing up
from a chair. The illness progressed slowly and over the next several years she developed mild
weakness in the shoulder muscles. Ten years after the initial symptoms she noted difficulties
in performing ankle dorsiflexion. Painful cramps in calf muscles were present from the disease
onset. No cardiac or respiratory symptoms were recorded. The patient was born in a Moldavian
village of about 4000 inhabitants, and moved to Spain with her brother. Their parents are
healthy and apparently unrelated. The patient's brother and son are clinically unaffected and
have normal CK levels. No cases of neuromuscular disease have been reported in other family
members. On examination, the facial and neck muscles had normal strength. She had marked
calf hypertrophy, muscle wasting involving the anterior and posterior compartments of the
thighs and distal anterior compartments of legs, and mild scapular winging and hyperlordosis
(Fig. 1). There was prominent weakness involving quadriceps (3/5), iliopsoas (4/5), hip
adductors (2/5), hip abductors (0/5), knee flexors (4/5), anterior tibialis (2/5), great toe (0/5)
and finger extensors (1/5). In the upper extremities weakness was restricted to the humeral
rotators (4/5) and biceps brachii (4/5). The patient was able to walk on heels, but not on toes.
Achilles tendons were tightened; deep tendon reflexes were hypoactive and sensation was
intact. CK level was at 1.826 U/L (normal < 167 U/L). EKG and echocardiography were
normal; EMG examination was consistent with myopathy. Muscle CT scan performed at the
age of 24 showed marked hypodensity of the glutei, biceps femoris, semimbranosus,
semitendinosus and quadriceps muscles contrasting with marked hypertrophy of the sartorius
and a relative preservation of the adductor longus. At mid-calf level, there was a selective
involvement of anterior tibialis muscle, more pronounced in the left leg (Fig. 2). Neurological
exam and CK levels in the patient's 26-year-old brother were normal.
3.2. Myopathology, immunofluorescence and Western blot analysis
Histopathological study revealed a wide variation in the fiber size ranging from 20 to 100 μm
with large numbers of hypotrophic rounded fibers of type I, central nuclei and mild increase
in endomysial connective tissue. Rimmed vacuoles were not observed, and there was no muscle
fiber necrosis or regeneration (Fig. 3A). On oxidative stain reactions, the atrophic type I fibers
appeared lobulated, whereas other fibers showed areas of irregular staining (Fig. 3B). ATPase
reaction revealed type I fiber predominance. Under electron microscopy, the overall sarcomeric
structure was preserved and only minor areas of myofibrillary disorganization were seen.
Immunofluorescence (Fig. 3C and D) and Western blot (Fig. 4) assays revealed lack of
telethonin in skeletal muscle. Dystrophin, the four sarcoglycans and dysferlin were preserved
both on immunohistochemistry and Western blots. Furthermore, Western blot to calpain
revealed normal band densities.
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Analysis of the patient's TCAP gene sequences identified a TGG-to-TGA substitution at codon
25 of exon 1 predicted to replace triptophan at this position with a stop signal (Trp25X) and
result in a truncated telethonin molecule which terminates at position 25 instead of normal 167
(GenBank Accession No. EU257805). This change was present on both chromosomes (Fig.
5). The early termination of transcription was confirmed by the absence of muscle telethonin
reactivity: the epitope to which the used antibody is directed is located at the C-terminal part
of telethonin, amino acids 58–167 (Santa Cruz Biotechnology, Inc., http://www.scbt.com/).
Both patient's parents and her brother were heterozygous for this mutation. The affected region
of the TCAP gene is highly conserved in the evolution (data not shown) and no irregularities
in this region were detected in 154 control individuals. This suggests that TCAP Trp25X is a
pathogenic myopathy-causing mutation. DNA sequence analysis ruled out mutations in the
FKRP gene.
4. Discussion
We have identified a patient with 2G type autosomal recessive limb-girdle muscular dystrophy
associated with a novel telethonin mutation. Even though LGMD 2G is considered a very rare
disorder, the results of immunohistochemical and Western blot studies showing normal
expression of dystrophin, sarcoglycans, dysferlin and calpain, the lack of mutations in FKRP
gene, and the clinical phenotype of the patient showing limb-girdle and anterior tibialis muscle
weakness and calf hypertrophy prompted us to investigate her for telethonin deficiency. This
is the first report of LGMD2G on the European continent. Previously reported LGMD2G
patients presented between 2 and 15 years of age with muscle weakness in the four limbs and
calf hypertrophy. Patients had marked weakness of distal anterior leg muscles, in some cases
already present from the onset of illness. Cardiomyopathy was suspected in three cases [1,2].
The patient reported in this communication developed proximal lower limb weakness and
marked calf hypertrophy at the age of 15 years. She also complained of frequent painful calf
cramps, a feature not reported in previous descriptions of LGMD2G. Detailed studies of this
patient established the distribution of skeletal muscle involvement as severe wasting of the
glutei and thigh muscles in the anterior and posterior compartments, selective atrophy of the
anterior tibialis, and mild involvement of limb-girdle muscles, a pattern generally different
from that observed in other forms of LGMD [12,13] and distal myopathies [14]. Muscle
biopsies performed in previously reported LGMD2G patients showed mild dystrophic changes,
type I fiber atrophy and complete telethonin deficiency. In 4 of 6 patients studied, rimmed
vacuoles were observed, although in a small proportion of fibers. Yet, only in one patient were
vacuolar changes prominent [3]. Similar pathological abnormalities, but without vacuoles,
were observed in our patient. Significantly, we found a large number of lobulated fibers, a
feature frequently observed in other forms of muscular dystrophy, especially in LGMD2A and
LGMD2B [13]. Clinical and myopathological features characteristic of LGMD2G therefore
overlap with other forms of recessive LGMD. The predominant involvement of pelvic girdle
muscles with calf hypertrophy observed in LGMD2G resembles the phenotype of some
LGMD2I patients. The lack of respiratory or cardiac involvement, which is frequently seen in
LGMD2I, and the severe atrophy of the quadriceps and anterior tibialis muscles observed in
LGMD2G help to differentiate the two conditions [12,13]. Prominent quadriceps and anterior
tibialis involvement and mild scapular winging distinguish LGMD2G from LGMD2A patients.
Finally, lack of involvement of posterior calf muscles distinguishes LGMD2G from the distal
anterior myopathy due to dysferlin deficiency [15]. Even with all these distinguishing signs, a
definitive diagnosis of LGMD2G cannot be based on clinical grounds alone.
Immunohistochemical, Western blot and molecular studies are necessary in each case of
autosomal recessive LGMD. However, the presence of telethonin in muscle biopsies is not
routinely investigated in patients suffering from LGMD [16,17]. Therefore, since as we show
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here, telethonin deficiency exists outside Brazil, appropriate diagnostic investigations are
indicated. This study confirms the existence and a wider than expected geographic distribution
of LGMD2G.
The frequency of TCAP Trp25X mutation among the Moldavian population is currently
unknown and requires further investigations. The patient's parents, originating from the same
village, were found heterozygous for the mutation; therefore the possibility that they have a
common ancestor cannot be ruled out.
Finally, the mechanism by which telethonin deficiency causes LGMD 2G is currently
unknown. The TCAP Trp25X mutation found in our patient probably prevents telethonin
interaction with titin and other proteins involved in the development and maintenance of
sarcomeric structure as well as intracellular signalling processes. Furthermore, it has been
recently shown that TCAP knockdown in cultured cells treated with short-interfering RNA
alters myogenic differentiation and is associated with decreased expression of Myo and
myogenin [18,19]. Further studies are necessary to investigate how telethonin deficiency
causes muscular dystrophy.
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LGMD2G patient with TCAP Trp25X mutation. Atrophy of the anterior and posterior thigh
muscles and anterior tibialis, marked calf hypertrophy.
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Muscle CT images at pelvic (A), mid-thigh (B), and mid-calf levels. There is marked
involvement of the gluteus maximus and anterior and posterior compartment muscles of the
thigh, while adductor longus is preserved and sartorius is markedly hypertrophic. At mid-calf
level, anterior tibialis are selectively involved (arrows).
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Muscle biopsy showing (A) wide variation in the fiber size with internal nuclei and mild
endomysial fibrosis. On NADH reaction with (B) most of the atrophic fibers are lobulated.
Lack of telethonin (C) as compared with normal sarcomeric labeling in the control (D). A, C
and D 200×; B 400×.
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Western blotting of muscle protein extracts to telethonin in patient with LGMD 2G (A, lane
5) compared with patients suffering from LGMD2I (A, lane 1), LGMD2B (A, lane 2), Becker
muscular dystrophy (A, lanes 3 and 4), myotilinopathy (A, lane 6), LGMD 2 A (A, lanes 7 and
8), and a healthy control (A, lane 9). Coomassie blue stain (B) is used as protein loading control.
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Nucleotide sequences of telethonin (TCAP) gene in a patient with LGMD 2G, her brother and
a control individual. A G-to-A transition changes TCAP codon 25 sequence from TGG to TGA
and results in a predicted substitution of tryptophan with Stop, thus terminating transcription
of telethonin at this early point. The patient shows the mutation on both chromosomes and is
therefore homozygous for this mutation; the unaffected sibling is heterozygous.
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